(NASDAQ: RNA) Avidity Biosciences's forecast annual revenue growth rate of 251.86% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 48.51%, and it is also forecast to beat the US market's average forecast revenue growth rate of 22.49%.
Avidity Biosciences's revenue in 2026 is $18,755,000.On average, 15 Wall Street analysts forecast RNA's revenue for 2026 to be $3,756,328,079, with the lowest RNA revenue forecast at $0, and the highest RNA revenue forecast at $10,654,126,191. On average, 11 Wall Street analysts forecast RNA's revenue for 2027 to be $46,085,650,848, with the lowest RNA revenue forecast at $11,824,109,671, and the highest RNA revenue forecast at $93,297,688,126.
In 2028, RNA is forecast to generate $137,892,350,875 in revenue, with the lowest revenue forecast at $71,873,073,510 and the highest revenue forecast at $234,275,965,460.